Abstract:Purpose: Regard preoperative chemotherapy as a holistic sequential treatment modality to identify predictive factors associated with recurrence and survival in pancreatic ductal adenocarcinoma (PDAC) and construct models to provide decision support and treatment selection for the candidate patients. Methods: Retrospect PDAC patients who received preoperative chemotherapy from January 2016 to June 2023 at the Second Affiliated Hospital of Zhejiang University School of Medicine. Run a univariate and multivariate analysis of factors associated with recurrence-free survival (RFS) and overall survival (OS). Scoring systems were developed based on the hazard ratios (HR) of all significant predictors. Kaplan–Meier analyses and log-rank tests were used to calculate RFS and OS. Results: A total of 72 PDAC patients with preoperative chemotherapy were analyzed. After preoperative chemotherapy, 21(29.17%) patients achieved any radiologic downstaging with 68(94.44%) patients achieving negative resection margin status (R0 margins). For carbohydrate antigen 19-9(CA19-9) non-secreting patients, shrinkage rate of length diameter of tumor≥20%(P=0.027), resection margin status(P=0.011) were independent predictors of OS. And for CA19-9 secreting patients, CA19-9 serum level at the end of chemotherapy≥1000(P=0.027) and resection margin status (P=0.012) were independent predictors of OS. Points according HR were allocated to these factors in the proposed scoring system, respectively. Recurrence curves and survival curves with statistically significant differences were also presented for patients grouped according to the scoring systems. For CA19-9 non-secreting patients, the OS of patients with a score from 2 to 2.97 was significantly shorter than that of patients with a score from 4.94 to 5.91 (P=0.009). And for CA19-9 secreting patients, the OS of patients with a score of 2 was significantly shorter than that of patients with a score from 3.75 to 4.99 (P<0.001). Conclusion: Simple scoring models for RFS and OS incorporating CA19-9 serum levels or the tumor shrinkage rate and postoperative pathology may assist clinicians in evaluating prognosis of PDAC patients with preoperative chemotherapy.

A Novel Online Calculator to Predict Recurrence Risk in Patients with Distal Cholangiocarcinoma after Radical Pancreaticoduodenectomy

Development and validation of an online calculator to predict early recurrence and long‐term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy

A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study

Prognostic Nomogram for patients undergoing radical Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head

Recurrence and Survival Prediction Models for Receiving Preoperative Chemotherapy Pancreatic Ductal Adenocarcinoma Cancer: A Single-center Retrospective Research

Development and validation of a prognostic nomogram to predict the recurrence of AFP-negative and DCP-positive hepatocellular carcinoma after curative resection

Nomogram and Competing Risk Model to Predict Recurrence after Curative Surgical Resection of PDAC

A Novel Prognostic Nomogram for Patients with Recurrence of Intrahepatic Cholangiocarcinoma after Initial Surgery.

Postoperative Serum Tumor Markers-Based Nomogram Predicting Early Recurrence for Patients Undergoing Radical Resections of Pancreatic Ductal Adenocarcinoma

Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy

Development and validation of a nomogram for predicting survival in patients with pancreatic ductal adenocarcinoma after radical pancreatoduodenectomy

Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy

Development and validation of nomograms based on pre-/post-operative CEA and CA19-9 for survival predicting in stage I-III colorectal cancer patients after radical resection

Development and Validation of a Nomogram for Preoperative Prediction of Early Recurrence after Upfront Surgery in Pancreatic Ductal Adenocarcinoma by Integrating Deep Learning and Radiological Variables

Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients with Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study.

Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Nomogram Model for Predicting Early Recurrence for Resectable Pancreatic Cancer：a Multicenter Study

A novel nomogram for adult primary perihilar cholangiocarcinoma and considerations concerning lymph node dissection

Establishment and Validation of a Prognostic Nomogram for Patients with Resectable Perihilar Cholangiocarcinoma

A Nomogram for Individual Prediction of Poor Prognosis after Radical Surgery in Patients with Primary Pancreatic Duct Adenocarcinoma.

Development and Validation of a Prognostic Score Predicting Recurrence in Resected Combined Hepatocellular Cholangiocarcinoma